Gland Pharma gain on getting GMP Compliance Certificate for Pashamylaram facility
Gland Pharma is currently trading at Rs 1870.00, up by 10.95 points or 0.59% from its previous closing of Rs 1859.05 on the BSE.
The scrip opened at Rs 1865.00 and has touched a high and low of Rs 1898.10 and Rs 1863.80 respectively. So far 2020 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 2220.95 on 06-Aug-2024 and a 52-week low of Rs 1200.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 1905.00 and Rs 1835.30 respectively. The current market cap of the company is Rs 30914.07 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.17% and 7.99% respectively.
Gland Pharma has received certificate of Good Manufacturing Practices (GMP) Compliance for its Pashamylaram facility from Danish Medicines Agency in connection with Marketing authorizations listing manufacturers located outside of the European Economic Area, for aseptically prepared Powder for injection, infusion and inhalation.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
